Supplement manufacturing facilities built for established and growing brands
White Bottle operates approximately 102,000 square feet across Stanton and Garden Grove, with 25 current production and packaging lines, planned expansion toward 37 lines, and available capacity for qualified programs.
Capacity is useful only when it matches the product and production pathway
The facility footprint combines formulation and commercialization support with capsule, powder, probiotic, blister, pouch, and bottling operations. Scheduling depends on the specific work centers and components a program needs.
Capsule production
Eight encapsulation machines support qualified HPMC and gelatin programs, with combined annual potential of up to approximately two billion capsules depending on program mix.
Powder production
In-house powder blending and filling support qualified collagen, creatine, protein, probiotic, and other supplement programs in jars, bottles, and pouches.
Blister packaging
Seven in-house blister lines support qualified capsules and other suitable solid-dose products with project-specific forming, lidding, card, and carton configurations.
Expansion planning
White Bottle currently reports 25 production and packaging lines with planned expansion toward 37, subject to installation, qualification, staffing, and operational readiness.
How capacity is evaluated for a specific program
A facility total does not automatically translate into a production promise. White Bottle evaluates the work centers, constraints, quality requirements, and commercial forecast together.
- Dosage form, formula complexity, material behavior, batch size, expected yields, cleaning, changeover, and line configuration
- Initial order, annual forecast, reorder cadence, growth case, launch timing, safety stock, seasonality, and requested lead time
- Raw-material and packaging-component qualification, supply, minimums, lead times, storage, and release status
- In-process and finished-product testing, laboratory turnaround, certification, stability, documentation, and quality-release requirements
- Primary and secondary packaging, tooling, artwork, print, coding, cartons, case packing, freight, and final delivery plan
Plan for both the launch batch and the credible growth case
A productive manufacturing relationship accounts for what the brand needs now and what changes if demand increases.
Launch readiness
Confirm formula, materials, package, artwork, specifications, methods, batch size, schedule, cost, and release requirements before committing to a date.
Reorder planning
Use forecasts, lead times, component availability, testing turnaround, inventory objectives, and seasonality to reduce avoidable production gaps.
Growth conversion
Identify when larger batches, different equipment, component changes, additional packaging capacity, or revised commercial terms may become appropriate.
A larger footprint does not mean every dosage form is made in-house
White Bottle’s facility story should remain specific to its actual production platform.
- In-house: capsules, powders, probiotic capsule and powder programs, blister packaging, pouches, and bottling
- Not represented as in-house dosage-form manufacturing: tablets, softgels, gummies, liquids, or stick packs
- Suitable externally produced tablets or softgels may be blister-packaged under an approved, clearly documented scope
- Outside manufacturing or packaging support, if relevant, should be disclosed and assigned in the quality and commercial agreements
Facility and capacity questions
Where are White Bottle’s facilities?
How large are White Bottle’s operations?
How many production lines does White Bottle have?
What is White Bottle’s capsule capacity?
Does available capacity mean immediate availability?
Match your forecast to the actual work centers and constraints
Share the product, batch and annual volume, package, timing, growth case, materials, testing, and certifications so White Bottle can assess project-specific capacity.